Financialization of the U.S. Pharmaceutical Industry
A takedown of the pharmaceutical industry’s assertion that it need to price gouge so it can invest in R&D. Profits go almost entirely to various forms of looting.
Read more...A takedown of the pharmaceutical industry’s assertion that it need to price gouge so it can invest in R&D. Profits go almost entirely to various forms of looting.
Read more...Nurses, or more accurately, nurse staffing levels demonstrate a central bad incentive in American medicine.
Read more...A short take on John Week’s new book, The Debt Delusion, and why it matters.
Read more...Why a Green New Deal looks like it will create a money, as in spending, as in inflation problem. Rest assured, there is an answer….
Read more...The upcoming UK election will usher in major change. But will it be change that benefits ordinary people?
Read more...Subprime loan repayment continues to deteriorate. What is going on?
Read more...How economists have contributed to climate change inaction.
Read more...Far from Brexit letting the UK takw back control, it has entered into a relationship where it holds none of the cards.
Read more...Discussion of a contested topic: How to pay for a Green New Deal.
Read more...A document leak gives chilling insight into the biggest detention of an ethnic group, the Uighurs, since the Holocaust.
Read more...Unpacking the many political and policy contradictions in Bolivia over the past decade.
Read more...The first major discussion of negative interest rates recounted in the FOMC minutes show serious disapproval.
Read more...Why most economists considerably underestimate the cost of climate change.
Read more...Private equity gets some long overdue scrutiny.
Read more...Private debt levels are even higher than in 2008 but super low interest rates make that look less worrisome than it arguably should be. T. Sabri Öncü ponders how to go about large scale debt relief.
Read more...